该局人用药品委员会(CHMP)的结论认为，吡罗昔康的益处仍大于其风险，但是，基于安全方面的考虑，其应用仅限于某些特定的适应症。
The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that piroxicam's benefits still outweigh its risks, but, based on safety grounds, only in certain, limited indications.
本文的第二章主要探讨了希罗·多德和修昔底德的史学方法。
In the second chapter, I mainly discuss the method of Herodotus and Thucydides.
然而，却有相当比例的患者的治疗使用了替非罗班——具有阿昔单抗的部分药理学特性。
However, a large proportion of patients in the community are treated with eptifibatide, an agent that shares some but not all pharmacological properties with abciximab.
应用推荐